<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="appear efficacious via systemic administration. A combination such as hydroxychloroquine," exact="azithromycin" post="and zinc, all of which have previously been used"/>
 <result pre="with into the nasopharynx accesses lungs and gut. â€¢Local hydroxychloroquine," exact="azithromycin" post="and zinc could block viral binding. â€¢This may offer"/>
 <result pre="anti-viral role. Crystallography studies demonstrate that while the ACE inhibitor" exact="lisinopril" post="binds in a region near the centre of the"/>
 <result pre="receptor near the N terminal [39], so direct blocking by" exact="lisinopril" post="of the virus attachment site seems unlikely. However, the"/>
 <result pre="of FDA-approved drug libraries identified a number of drugs including" exact="chloroquine" post="as potentially having anti-coronavirus actions [71] and therefore potentially"/>
 <result pre="(for SARS-CoV-2-unrelated disease) In Vivo In Vitro Clinical Human Animal" exact="Chloroquine" post="Phosphate +72 -a73 Â±74 +75,76(0.03%) 0 OHChloroquine +72 0"/>
 <result pre="-a73 Â±74 +75,76(0.03%) 0 OHChloroquine +72 0 Â±74 0 0" exact="Azithromycin" post="+77 0 Â±77 +78,79(1â€&quot;1.5% +80,81 (0.2â€&quot;1.5%) Zinc +aa82s 0"/>
 <result pre="denotes equivocal results, 0 denotes lack of studies. aFor SARS-CoV." exact="Chloroquine" post="has long been used in the treatment of malaria"/>
 <result pre="well as in oncology and for pediatric inflammatory disease. However," exact="chloroquine" post="has direct antiviral effects, inhibiting pH-dependent steps of the"/>
 <result pre="to interfere with terminal glycosylation of ACE2 [[87], [88], [89]]." exact="Chloroquine" post="also has immuno-modulatory effects [86,90], suppressing the production/release of"/>
 <result pre="severe inflammatory cascade associated with severe COVID-19 disease [86]. Recently," exact="hydroxychloroquine" post="was found to be more potent than chloroquine at"/>
 <result pre="[86]. Recently, hydroxychloroquine was found to be more potent than" exact="chloroquine" post="at inhibiting SARS-CoV-2 in vitro [91], fortuitous, since it"/>
 <result pre="derivative [92]. A recent systematic review of clinical trials utilising" exact="chloroquine" post="or hydroxychloroquine [74] concluded that 5/7 trials had shown"/>
 <result pre="A recent systematic review of clinical trials utilising chloroquine or" exact="hydroxychloroquine" post="[74] concluded that 5/7 trials had shown favorable outcomes"/>
 <result pre="study, a pilot observational study [93] showed that use of" exact="hydroxychloroquine" post="and azithromycin demonstrated apparent improved clinical outcomes in 65/80"/>
 <result pre="pilot observational study [93] showed that use of hydroxychloroquine and" exact="azithromycin" post="demonstrated apparent improved clinical outcomes in 65/80 patients, expanding"/>
 <result pre="are needed and have been called for [74]. While systemic" exact="chloroquine" post="and its derivatives appear to be associated with relatively"/>
 <result pre="[94] and this may be exacerbated by combination treatment with" exact="azithromycin" post="[74]. The well-known association with irreversible visual loss due"/>
 <result pre="concert with zinc have been explained by the fact that" exact="chloroquine" post="acts as a zinc ionophore [100], significantly, inhibiting cellular"/>
 <result pre="viral replication. For this reason, combination treatment for Covid-19 with" exact="chloroquine" post="and zinc has been suggested [102], although this intervention"/>
 <result pre="have all been used topically in the eye (Table 2)." exact="Chloroquine" post="as 0.03% chloroquine phosphate eye drops have apparently been"/>
 <result pre="used topically in the eye (Table 2). Chloroquine as 0.03%" exact="chloroquine" post="phosphate eye drops have apparently been efficacious in the"/>
 <result pre="effects were not reported, however there is a report of" exact="chloroquine" post="keratopathy in workers chronically exposed to chloroquine dust [103]."/>
 <result pre="a report of chloroquine keratopathy in workers chronically exposed to" exact="chloroquine" post="dust [103]. Chronic usage is unlikely in the setting"/>
 <result pre="glaucoma [104]. In this class of drugs, agents such as" exact="telmisartan" post="are long acting, with a mean half-life of 24Â"/>
 <result pre="drops or as an excipient, zinc sulphate (0.25%) [83]. Since" exact="chloroquine" post="and ACE2 inhibitors seem to act at different parts"/>
 <result pre="a risk factor for infection but these are unconfirmed [107]." exact="Azithromycin" post="has also previously been safely used topically in the"/>
 <result pre="initial local delivery of a combination of chloroquine, zinc and" exact="azithromycin" post="to the eyelids and ocular surface with eye drops"/>
 <result pre="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488424841269 72WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="Chem Chemother17200627528417176632 74ChowdhuryM.S.RathodJ.GernsheimerJ.A rapid systematic review of clinical trials utilizing" exact="chloroquine" post="and hydroxychloroquine as a treatment for COVID-19Acad Emerg Med2020"/>
 <result pre="74ChowdhuryM.S.RathodJ.GernsheimerJ.A rapid systematic review of clinical trials utilizing chloroquine and" exact="hydroxychloroquine" post="as a treatment for COVID-19Acad Emerg Med2020 May 210.1111/acem.14005.Mar9:ciaa237"/>
 <result pre="May 210.1111/acem.14005.Mar9:ciaa237 75BhavsarAnkita SamirBhavsarSamir G.JainSunita M.Evaluation of the effects of" exact="chloroquine" post="phosphate eye drops in patients with dry eye syndromeInt"/>
 <result pre="syndromeInt J Biomed Adv Res22011198214 76TitiyalJ.S.KaurM.FaleraR.BharghavaA.SahR.SenS.Efficacy and safety of topical" exact="chloroquine" post="in mild to moderate dry eye diseaseCurr Eye Res4420191306131231283891"/>
 <result pre="Eye Res4420191306131231283891 77DamleB.VourvahisM.WangE.Clinical pharmacology perspectives on the antiviral activity of" exact="azithromycin" post="and use in COVID-19Clin Pharmacol Ther2020 Apr 1710.1002/cpt.1857 78OpitzD.L.HarthanJ.S.Review"/>
 <result pre="and use in COVID-19Clin Pharmacol Ther2020 Apr 1710.1002/cpt.1857 78OpitzD.L.HarthanJ.S.Review of" exact="azithromycin" post="ophthalmic 1% solution (AzaSite(Â®)) for the treatment of ocular"/>
 <result pre="79AmzaA.GoldschmidtP.EinterzE.Elimination of active trachoma after two topical mass treatments with" exact="azithromycin" post="1.5% eye dropsPLoS Neglected Trop Dis4112010e895 80KuehneJ.J.YuA.L.HollandG.N.Corneal pharmacokinetics of"/>
 <result pre="eye dropsPLoS Neglected Trop Dis4112010e895 80KuehneJ.J.YuA.L.HollandG.N.Corneal pharmacokinetics of topically applied" exact="azithromycin" post="and clarithromycinAm J Ophthalmol138200454755315488779 81TabbaraK.F.KotbA.A.HammoudaE.F.Effects of dehydration on corneal"/>
 <result pre="Ophthalmol138200454755315488779 81TabbaraK.F.KotbA.A.HammoudaE.F.Effects of dehydration on corneal tissue absorption of topical" exact="azithromycin" post="in rabbitsCurr Eye Res30200591591816251129 82te VelthuisA.J.van den WormS.H.SimsA.C.BaricR.S.SnijderE.J.van HemertM.J.Zn(2+)"/>
 <result pre="cause more damage than help fight COVID-19Microb Infect202020S1286S457930071-X 86SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: an old drug against today's diseases?Lancet"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="vitroCell Discovery62020161932194981 93GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a combination of" exact="hydroxychloroquine" post="and azithromycin in 80 COVID-19 patients with at least"/>
 <result pre="93GautretP.LagierJ.C.ParolaP.Clinical and microbiological effect of a combination of hydroxychloroquine and" exact="azithromycin" post="in 80 COVID-19 patients with at least a six-day"/>
 <result pre="studyTrav Med Infect Dis2020 Apr 11101663 94SalehM.GabrielsJ.ChangD.The effect of chloroquine," exact="hydroxychloroquine" post="and azithromycin on the corrected QT interval in patients"/>
 <result pre="Infect Dis2020 Apr 11101663 94SalehM.GabrielsJ.ChangD.The effect of chloroquine, hydroxychloroquine and" exact="azithromycin" post="on the corrected QT interval in patients with SARS-CoV-2"/>
 <result pre="Apr 29Circ Arrhythm Electrophysiol 95YusufI.H.SharmaS.LuqmaniR.DownesS.M.Hydroxychloroquine retinopathyEye31201782884528282061 96PasaogluI.OnmezF.E.Macular toxicity after short-term" exact="hydroxychloroquine" post="therapyIndian J Ophthalmol67201928929230672499 97ShroyerN.F.LewisR.A.LupskiJ.R.Analysis of the ABCR (ABCA4) gene"/>
 <result pre="ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by" exact="chloroquine" post="and hydroxychloroquine related to Stargardt disease?Am J Ophthalmol131200176176611384574 98HednerT.SamulessonO.WÃ¤hrborgP.WadenvikH.UngK.A.EkbomA.Nabumetone:"/>
 <result pre="gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and" exact="hydroxychloroquine" post="related to Stargardt disease?Am J Ophthalmol131200176176611384574 98HednerT.SamulessonO.WÃ¤hrborgP.WadenvikH.UngK.A.EkbomA.Nabumetone: therapeutic use"/>
 <result pre="souffrant de toxicitÃ© maculaire aux antipaludÃ©ens de synthÃ¨se [Variability of" exact="chloroquine" post="and hydroxychloroquine retinopathy among various ethnicities]J Fr Ophtalmol41201836336729678344 100XueJ.MoyerA.PengB.WuJ.HannafonB.N.DingW.Q.Chloroquine"/>
 <result pre="toxicitÃ© maculaire aux antipaludÃ©ens de synthÃ¨se [Variability of chloroquine and" exact="hydroxychloroquine" post="retinopathy among various ethnicities]J Fr Ophtalmol41201836336729678344 100XueJ.MoyerA.PengB.WuJ.HannafonB.N.DingW.Q.Chloroquine is a"/>
 <result pre="of viral RNA-dependent RNA polymeraseJ Virol912017e00754-17 102ShittuM.O.AfolamiO.I.Improving the efficacy of" exact="Chloroquine" post="and Hydroxychloroquine against SARS-CoV-2 may require Zinc additives -"/>
 <result pre="RNA-dependent RNA polymeraseJ Virol912017e00754-17 102ShittuM.O.AfolamiO.I.Improving the efficacy of Chloroquine and" exact="Hydroxychloroquine" post="against SARS-CoV-2 may require Zinc additives - a better"/>
 <result pre="future COVID-19 clinical trialsInf Med282020192197Ahead of print 103EriksenL.S.Chloroquine keratopathy in" exact="chloroquine" post="workers after topical dust exponation. A case reportActa Ophthalmol571979823825525306"/>
 <result pre="Virol2020 Mar 16e210310.1002/rmv.2103Epub ahead of print. PMID: 32175637 108TettS.E.CutlerD.J.DayR.O.BrownK.F.Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteersBr J Clin Pharmacol2719897717792757893 109XuH.ZhongL.DengJ.PengJ.DanH.ZengX.LiT.ChenQ.High expression"/>
</results>
